All cases of endometrial cancer occurring among the residents of an affluent retirement community were compared with controls chosen from a roster of all women in the same community. Evidence of estrogen and other drug use and of selected medical conditions was obtained from three sources: medical records of the principal care facility, interviews, and the records of the local pharmacy. The risk ratio for any estrogen use was estimated from all available evidence to be 8.0 (95 per cent confidence interval, 3.5 to 18.1). and the for conjugated estrogen use to be 5.6 (95 per cent confidence interval, 2.8 to 11.1). Increased risk from estrogens was shown for invasive as well as noninvasive cancer, and a dose-response effect was demonstrated. For an estrogen user, the risk from endometrial cancer appeared to exceed by far the base-line risk from any other single cancer.
This article has been cited by other articles:
Gargas, M. L., Sweeney, L. M., Himmelstein, M. W., Pottenger, L. H., Bus, J. S., Holder, J. W.
(2008). Physiologically based Pharmacokinetic Modeling of Chloroethane Disposition in Mice, Rats, and Women. Toxicol Sci
104: 54-66
[Abstract][Full Text]
Linet, M. S.
(2008). Invited Commentary: Postmenopausal Unopposed Estrogen and Breast Cancer Risk in the Women's Health Initiative--Before and Beyond. Am J Epidemiol
167: 1416-1420
[Abstract][Full Text]
Weiss, J. M., Saltzman, B. S., Doherty, J. A., Voigt, L. F., Chen, C., Beresford, S. A. A., Hill, D. A., Weiss, N. S.
(2006). Risk Factors for the Incidence of Endometrial Cancer according to the Aggressiveness of Disease. Am J Epidemiol
164: 56-62
[Abstract][Full Text]
Xu, W. H., Matthews, C. E., Xiang, Y. B., Zheng, W., Ruan, Z. X., Cheng, J. R., Gao, Y. T., Shu, X. O.
(2005). Effect of Adiposity and Fat Distribution on Endometrial Cancer Risk in Shanghai Women. Am J Epidemiol
161: 939-947
[Abstract][Full Text]
Davis, S R, Dinatale, I, Rivera-Woll, L, Davison, S
(2005). Postmenopausal hormone therapy: from monkey glands to transdermal patches. J Endocrinol
185: 207-222
[Abstract][Full Text]
De Vivo, I., Huggins, G. S., Hankinson, S. E., Lescault, P. J., Boezen, M., Colditz, G. A., Hunter, D. J.
(2002). A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc. Natl. Acad. Sci. USA
99: 12263-12268
[Abstract][Full Text]
Bush, T. L., Whiteman, M., Flaws, J. A.
(2001). Hormone Replacement Therapy and Breast Cancer: A Qualitative Review. Obstet Gynecol
98: 498-508
[Abstract][Full Text]
Mills, L. H., Lee, A. J., Parlow, A. F., Zhu, B. T.
(2001). Preferential Growth Stimulation of Mammary Glands over Uterine Endometrium in Female Rats by a Naturally Occurring Estradiol-17{beta}-fatty Acid Ester. Cancer Res.
61: 5764-5770
[Abstract][Full Text]
Arnett-Mansfield, R. L., deFazio, A., Wain, G. V., Jaworski, R. C., Byth, K., Mote, P. A., Clarke, C. L.
(2001). Relative Expression of Progesterone Receptors A and B in Endometrioid Cancers of the Endometrium. Cancer Res.
61: 4576-4582
[Abstract][Full Text]
Feeley, K M, Wells, M
(2001). Hormone replacement therapy and the endometrium. J. Clin. Pathol.
54: 435-440
[Abstract][Full Text]
GOLDSTEIN, S. R., SCHEELE, W. H., RAJAGOPALAN, S. K., WILKIE, J. L., WALSH, B. W., PARSONS, A. K.
(2000). A 12-Month Comparative Study of Raloxifene, Estrogen, and Placebo on the Postmenopausal Endometrium. Obstet Gynecol
95: 95-103
[Abstract][Full Text]
Rose, P. G.
(1996). Endometrial Carcinoma. NEJM
335: 640-649
[Full Text]
Voda, A. M.
(1994). Risks and Benefits Associated with Hormonal and Surgical Therapies for Healthy Midlife Women. West J Nurs Res
16: 507-523
[Abstract]
Henderson, B., Ross, R., Pike, M.
(1993). Hormonal chemoprevention of cancer in women. Science
259: 633-638
[Abstract]
Gordis, L, Gold, E
(1980). Privacy, confidentiality, and the use of medical records in research. Science
207: 153-156
Previous
